Rhinosinusitis is an indication for drug development with over 30 pipeline drugs currently active. According to GlobalData, preregistered drugs for Rhinosinusitis have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Rhinosinusitis compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Rhinosinusitis overview
Rhinosinusitis is a condition that affects the nasal and sinus mucosa, causing inflammation and symptoms such as nasal congestion, discharge, pain, and loss of smell. It can be classified into acute or chronic, depending on the duration of the illness. Acute rhinosinusitis usually lasts less than four weeks and is often caused by viral or bacterial infections. Chronic rhinosinusitis lasts more than 12 weeks and is often associated with allergies, nasal polyps, deviated septum, or fungal infections. Rhinosinusitis can be diagnosed by history, physical examination, and sometimes by nasal or sputum culture or CT scan. Treatment options include pain relievers, decongestants, nasal irrigation, topical steroids, antibiotics, and surgery in some cases. Rhinosinusitis can affect the quality of life and lead to complications such as sleep apnea and orbital or intracranial infections if left untreated.
For a complete picture of PTSR and LoA scores for drugs in Rhinosinusitis, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
